已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis

阿柏西普 医学 血管抑制剂 贝伐单抗 眼科 视力 科克伦图书馆 不利影响 糖尿病性黄斑水肿 荟萃分析 黄斑水肿 子群分析 糖尿病性视网膜病变 内科学 糖尿病 化疗 内分泌学
作者
Yilin Liu,Jiahan Cheng,Yunxia Gao,Ling Qin,Xiaoxue Min,Ming Zhang
出处
期刊:Annals of Translational Medicine [AME Publishing Company]
卷期号:8 (6): 382-382 被引量:20
标识
DOI:10.21037/atm.2020.02.04
摘要

BACKGROUND: To evaluate functional and anatomical consequences of switching anti-vascular endothelial growth factor (anti-VEGF) therapy from bevacizumab and/or ranibizumab to aflibercept intravitreal injection for the treatment of persistent diabetic macular edema (DME). METHODS: Analysis of switching treatment in patients with persistent DME was performed using a literature search across multiple databases (PubMed, Medline, EMBASE, Cochrane Library and Web of Science) prior to May 2019. Therapeutic effect parameters, including mean change of best-corrected visual acuity (BCVA) and central macular thickness (CMT), were extracted from baseline to different follow-up times post initial injections. The quality of studies was assessed with the Downs and Black checklist. Data pertaining to ocular and systemic safety adverse events (SAEs) were collected as well as subgroup analysis stratified by pre-switch anti-VEGF reagents. All results were analyzed and pooled using random-effects models with 95% confidence intervals (CI). RESULTS: Fourteen studies involving 489 eyes met the inclusion criteria. The mean differences in BCVA were significantly improved at 1, 2 and 3 months with -0.11 logMAR (P=0.016), -0.22 logMAR (P<0.001) and -0.24 logMAR (P<0.01), respectively. Vision gain was also assessed following the aflibercept injection with a mean change of -0.10 logMAR (P<0.001) at 6 months and -0.08 logMAR (P=0.01) at 12 months. CMT reduction was significant from baseline with a mean decrease of 80.52 µm (P<0.001) at 1 month, 89.6 µm (P<0.013) at 2 months, 113.88 µm (P<0.001) at 3 months and 125.12 µm (P<0.001) at 6 months. Mean CMT continued to decline by 75.70 µm (P<0.001) at 12 months as well. CONCLUSIONS: This meta-analysis indicated the comparable efficacy and safety of a conversion treatment to aflibercept in cases of unsatisfactory responses to other anti-VEGF drugs. Switching treatment produces significant advantage for vision acuity recovery and macular edema improvement among persistent DME patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1234发布了新的文献求助10
1秒前
nini完成签到,获得积分10
1秒前
1秒前
南城发布了新的文献求助10
1秒前
阿宁完成签到 ,获得积分10
1秒前
爆米花的应助被Waitcy采纳,获得10
2秒前
2秒前
Rina发布了新的文献求助10
3秒前
liuxi12138完成签到,获得积分10
3秒前
5秒前
一锅炖不下完成签到,获得积分20
7秒前
xcgh给法就的求助进行了留言
7秒前
YBadada完成签到,获得积分10
8秒前
unik完成签到,获得积分10
8秒前
潘森爱科研完成签到,获得积分10
9秒前
Jane发布了新的文献求助10
9秒前
领导范儿的应助被LIUDAN采纳,获得10
12秒前
ralph_liu完成签到,获得积分10
12秒前
12秒前
cnspower的应助被JiuJiu采纳,获得30
13秒前
格物致知完成签到,获得积分10
13秒前
SciGPT的应助被hejiacheng采纳,获得50
14秒前
英俊的铭的应助被Rina采纳,获得10
14秒前
Owen的应助被Jane采纳,获得10
14秒前
Tori发布了新的文献求助50
14秒前
15秒前
某个不想做人的dio完成签到,获得积分10
16秒前
16秒前
shenxian82133发布了新的文献求助10
16秒前
17秒前
Maestro_S的应助被nuodei采纳,获得10
18秒前
是驼驼呀完成签到,获得积分10
18秒前
19秒前
Non发布了新的文献求助30
20秒前
21秒前
飘逸的苡发布了新的文献求助20
22秒前
22秒前
rebecca发布了新的文献求助10
22秒前
23秒前
影月cindy的应助被西西采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194612
求助须知:如何正确求助?哪些是违规求助? 9580394
关于积分的说明 21870930
捐赠科研通 7794182
什么是DOI,文献DOI怎么找? 3437711
关于科研通互助平台的介绍 2561001
邀请新用户注册赠送积分活动 2484411